Christensen Erik
Ugeskr Laeger. 2019 Jan 7;181(2).
There is increasing evidence of gut dysbiosis being a significant factor in the development and progression of important chronic liver diseases including non-alcoholic steatohepatitis (NASH), alcoholic liver disease, primary sclerosing cholangitis and cirrhosis. Dysbiotic microbiota and their toxic metabolites translocate across the gut epithelium via the portal vein and cause damage to the liver. In NASH, alcohol-producing gut bacteria may be critical for its development. Therapeutic measures to normalise the gut microbiota with diet, probiotics or transplantation of normal microbiota seem to have a beneficial effect.
越来越多的证据表明,肠道微生物群失调是包括非酒精性脂肪性肝炎(NASH)、酒精性肝病、原发性硬化性胆管炎和肝硬化在内的重要慢性肝病发生和发展的重要因素。失调的微生物群及其有毒代谢产物通过门静脉穿过肠道上皮,对肝脏造成损害。在NASH中,产生酒精的肠道细菌可能对其发展至关重要。通过饮食、益生菌或正常微生物群移植来使肠道微生物群正常化的治疗措施似乎具有有益效果。